Related Experiment Videos
[A comparative study of cefepime for bacterial pneumonia]
1First Department of Internal Medicine, Faculty of Medicine, University of The Ryukys.
Abstract:
The efficacy, safety and usefulness of cefepime (CFPM), a new cephem antibiotic, in bacterial pneumonia, were evaluated in a comparative study against ceftazidime (CAZ). Each drug was administered by intravenous drip infusion at a dose of 1.0 g (nominal potency) twice daily for 14 days, and the following results were obtained. 1. A total of 183 cases were enrolled in this study. Efficacy rates ("good" or better responses) as evaluated by the subcommittee were 90.3% (65/72) in the CFPM group and 94.0% (63/67) in the CAZ group, with no significant difference between the 2 groups. 2. Efficacy rates ("good" or better responses), as evaluated by attending physicians, (in the same bacterial pneumonia cases which were subjected to evaluation by the subcommittee) were 87.5% (63/72) in the CFPM group and 89.6% (60/67) in the CAZ group, with no significant difference between the 2 groups. 3. Bacteriologically, eradication rates were 96.9% (31/32) in the CFPM group and 96.7% (29/30) in the CAZ group with no significant difference between the 2 groups. 4. The incidence of side effects was 5.9% (5/85) in the CFPM group and 4.8% (4/84) in the CAZ group, with no significant difference between the 2 groups. No significant difference was also found between the 2 groups in the incidence of abnormal laboratory findings; 28.4% (23/81) of the case in the CFPM group and 34.1% (28/82) in the CAZ group. 5. As for overall usefulness of the drug in bacterial pneumonia cases, utility rates ("useful" or better evaluations) as evaluated by the subcommittee were 88.9% (64/72) in the CFPM group and 92.5% (62/67) in the CAZ group. The rates as evaluated by investigators (in cases judged as evaluable by the subcommittee) were 87.5% (63/72) and 85.1% (57/67), respectively. There were no significant differences between the 2 groups. These results indicated that CFPM is very useful for the treatment of bacterial pneumonia.
Insights
Cefepime (CFPM) and ceftazidime (CAZ) showed similar efficacy and safety in treating bacterial pneumonia. Both antibiotics demonstrated high efficacy rates, low side effect incidence, and comparable usefulness in this comparative study.
Area of Science:
- Infectious Diseases
- Pharmacology
- Critical Care Medicine
Background:
- Bacterial pneumonia remains a significant cause of morbidity and mortality worldwide.
- The development of effective antibiotic therapies is crucial for managing this condition.
- Novel antibiotics like cefepime (CFPM) require rigorous evaluation against established treatments such as ceftazidime (CAZ).
Purpose of the Study:
- To compare the efficacy, safety, and usefulness of cefepime (CFPM) against ceftazidime (CAZ) in patients with bacterial pneumonia.
- To assess clinical response, microbiological eradication, and adverse events associated with both antibiotic regimens.
- To determine the overall utility of CFPM as a treatment option for bacterial pneumonia.
Main Methods:
- A comparative study involving 183 patients diagnosed with bacterial pneumonia.
- Intravenous drip infusion of either CFPM or CAZ at 1.0 g twice daily for 14 days.
- Evaluation of efficacy by subcommittee and attending physicians, bacteriological eradication rates, incidence of side effects, and abnormal laboratory findings.
Main Results:
- Clinical efficacy rates were high and comparable between CFPM (90.3%) and CAZ (94.0%) by subcommittee evaluation, and (87.5% vs. 89.6%) by physician evaluation.
- Bacteriological eradication rates were excellent and similar for both drugs (96.9% for CFPM vs. 96.7% for CAZ).
- The incidence of side effects (5.9% vs. 4.8%) and abnormal laboratory findings (28.4% vs. 34.1%) were not significantly different between the CFPM and CAZ groups.
Conclusions:
- Cefepime (CFPM) demonstrates comparable efficacy, safety, and usefulness to ceftazidime (CAZ) in the treatment of bacterial pneumonia.
- CFPM is a valuable therapeutic option for managing bacterial pneumonia, offering similar outcomes to CAZ.
- The study supports the use of CFPM as an effective antibiotic for bacterial pneumonia based on clinical and microbiological data.